Craft

Amicus Therapeutics

Stock Price

$11.5

2024-03-22

Market Capitalization

$3.4 B

2024-03-22

Revenue

$399.4 M

FY, 2023

Amicus Therapeutics Summary

Company Summary

Overview
Amicus Therapeutics is a biopharmaceutical company developing oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. The Company is focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. It is initially targeting lysosomal storage disorders and continues to develop its pharmacological chaperone technology having built an intellectual property portfolio along with its robust clinical and preclinical pipeline.
Type
Public
Status
Active
Founded
2002
HQ
Philadelphia, PA, US | view all locations
Website
http://www.amicusrx.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • John F. Crowley

    John F. Crowley, Chairman and Chief Executive Officer

    • Margaret G. McGlynn, Director

      • Robert Essner, Director

        • Lynn D. Bleil, Director

          LocationsView all

          11 locations detected

          • Philadelphia, PA HQ

            United States

            3675 Market St

          • Northbridge, NSW

            Australia

            21 Dorset Rd

          • Pointe-Claire, QC

            Canada

            6500 TransCanada Service Rd, 4th Floor

          • Paris, IDF

            France

            12 Place de la Défense

          • München, BY

            Germany

            Willy-Brandt-Platz

          • Dublin, D

            Ireland

            Block 1, Blanchardstown Corporate Park, Ballycoolin Rd, Ballycoolen

          and 5 others

          Amicus Therapeutics Financials

          Summary Financials

          Revenue (FY, 2023)
          $399.4M
          Gross profit (FY, 2023)
          $362.0M
          Net income (FY, 2023)
          ($151.6M)
          Cash (FY, 2023)
          $247.0M
          EBIT (FY, 2023)
          ($77.2M)
          Enterprise value
          $3.6B

          Footer menu